David A. Siegel Travere Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 553,300 shares of TVTX stock, worth $10.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
553,300
Previous 700,200
20.98%
Holding current value
$10.5 Million
Previous $5.4 Million
15.75%
% of portfolio
0.01%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding TVTX
# of Institutions
187Shares Held
89.5MCall Options Held
137KPut Options Held
184K-
Black Rock Inc. New York, NY7.64MShares$145 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$143 Million0.8% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$140 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.62MShares$126 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.48MShares$85.3 Million1.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.22B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...